A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Novo Nordisk

Status

Completed

Conditions

Obesity or Overweight

Treatments

Drug: Saxenda®

Study type

Observational

Funder types

Industry

Identifiers

NCT05153590

NN8022-4823

U1111-1263-5715 (Other Identifier)

Details and patient eligibility

About

The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients.

The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or overweight. Saxenda® was prescribed to participants by study doctor independently of this study.

The study will last for about 4 months, where the data will be collected from the available medical records.

There will be no additional activities expected from participants in the scope of study because it is a chart-review study.

Enrollment

269 patients

Sex

All

Ages

18 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed consent (general consent for research or study-specific informed consent) obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, aged 18 to 74 years (both inclusive) at the time of Saxenda® initiation.
Have been prescribed Saxenda® for weight management.
For the reimbursed cohort, per the Swiss reimbursement criteria: BMI greater than or equal to 35 kg/m^2 or a BMIgreater than or equal to 28 and below 35 kg/m^2 with additional weight related comorbidities (pre diabetes or T2D (Type 2 Diabetes Mellitus), hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
For the non-reimbursed cohort, BMI greater than or equal to 30 kg/m^2 or a BMI greater than or equal to 28 kg/m^2 with additional weight related comorbidities (pre diabetes or T2D, arterial hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
The decision to initiate treatment with commercially available Saxenda® has been made by the patient/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Baseline weight measurement within 3 months of Saxenda® initiation/prescription.
At least one weight assessment post-Saxenda® initiation/prescription.

Exclusion criteria

Previous participation in this study. Participation is defined as having given informed consent in this study.
Treatment with any investigational drug within 30 days of Saxenda® prescription/initiation.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Concomitant treatment of Saxenda® with other GLP 1 (Glucagon-like peptide-1) receptor agonists, or orlistat.
Concomitant treatment with sodium/glucose cotransporter-2 inhibitors (SGLT 2i), dipeptidyl peptidase-4 (DPP 4i), or insulin for the reimbursed cohort only.
Patients who have been treated with any obesity medication for last 12 weeks prior to initiation of Saxenda® treatment.
Patients who have previously been treated with a GLP 1 receptor agonist for the reimbursed cohort only.
Patients who have undergone bariatric surgery at any time before starting Saxenda® treatment.
Patients initiating Saxenda® treatment after 31 October 2020.